絞り込み

16638

広告

Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry.

著者 MacKenzie-Graham A , Brook J , Kurth F , Itoh Y , Meyer C , Montag MJ , Wang HJ , Elashoff R , Voskuhl RR
Brain Behav.2018 Aug 24 ; ():e01086.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Medical

Miscellaneous

Progressive gray matter (GM) atrophy is a hallmark of multiple sclerosis (MS). Cognitive impairment has been observed in 40%-70% of MS patients and has been linked to GM atrophy. In a phase 2 trial of estriol treatment in women with relapsing-remitting MS (RRMS), higher estriol levels correlated with greater improvement on the paced auditory serial addition test (PASAT) and imaging revealed sparing of localized GM in estriol-treated compared to placebo-treated patients. To better understand the significance of this GM sparing, the current study explored the relationships between the GM sparing and traditional MRI measures and clinical outcomes.
PMID: 30144306 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード